Role of blood-brain barrier, innate immunity, and tau protein oligomerization in the pathogenesis of Alzheimer's disease

Project of the Croatian Science Foundation grant no. IP-2019-04-3584 (15 Jan 2020 - 14 Jan 2024)

 

Uloga krvno-moždane barijere, urođene imunosti i oligomerizacije tau proteina u patogenezi Alzheimerove bolesti

Projekt Hrvatske zaklade za znanost br. IP-2019-04-3584 (15. siječnja 2020. - 14. siječnja 2024. godine)

 

Hrvatska zaklada za znanost Croatian Science Foundation

 

Poveznica na prethodni HRZZ projekt / Link to the previous CSF project

 

Project collaborators / Suradnici na projektu:

Velimir Altabas, Mirjana Babić Leko, Danira Bažadona, Antonela Blažeković, Marina Boban, Mirta Boban, Srećko Branica, Lea Langer Horvat, Dražen Huić, Vesna Lukinović-Škudar, Ana Mlinarić, Martina Rinčić, Ankica Sekovanić, Ena Španić, Željka Vogrinc, Klara Zubčić

Project leader / Voditelj projekta:

Goran Šimić

 

Summary of the project

The amyloid cascade hypothesis explains familial cases of Alzheimer’s disease (AD) with known mutations, but is insufficient to explain sporadic, late-onset AD that accounts for over 95% of all cases. Genetic and experimental studies have implicated microglial dysfunction and blood-brain barrier (BBB) disruption as causal factors for AD. We propose an in-depth analysis of these aspects of the disease that may contribute mechanistically to the development of tau protein aggregation and neurofibrillary lesions, which show the highest correlation with clinical symptoms and progression of AD. Our aims are: 1. To examine the relationships between cognitive status of healthy controls (HC), subjects with mild cognitive impairment (MCI) and AD subjects with blood and cerebrospinal fluid (CSF) markers of innate immune activation; a battery of neuropsychological tests, MRI analysis of cortical atrophy, auditory event-related potentials will be performed, and cognition assessed by the hidden-goal test using the ALZENTIA® system we developed; 2. To determine the BBB permeability in HC, MCI, and AD subjects by measuring CSF/blood albumin ratio and levels of neurofilament light chain and S100B proteins, as well as concentrations of 24 metal, metalloids, and trace elements; 3. To evaluate neuroimmune activation in the 3 groups through assessment of CSF and blood TNF?, IL-1ß, VILIP-1, YKL-40, sTREM2, MCP1, CCL3, CCL4, and eotaxin-3, and postmortem tissue markers of neuroinflammation and M1 microglial activation (C1q, CD11b, CD68, CX3CR1, HLA-DR, IBA1, TREM2) and through immunocytochemical analysis of BBB integrity (AQP4 channels, collagen type IV) and function (LRP1, VDRLR, and RAGE receptors) in HC and AD brains as well as in Wistar rats inoculated with pathological tau oligomers; and 4. To construct a luminescent reporter for monitoring human tau oligomerization in living yeast cells, which we will use to examine the effect of proteotoxic stress and aging on tau oligomerization.

 

Sažetak projekta

Hipoteza amiloidne kaskade dobro objašnjava obiteljske slucajeve Alzheimerove bolesti (AD) s poznatim mutacijama, ali je nedostatna za razumijevanje nastanka sporadicne AD s kasnim pocetkom koja cini više od 95% svih slucajeva AD. Geneticka i eksperimentalna istraživanja ukazuju da bi disfunkcija mikroglije i povecana propusnost krvno-moždane barijere (BBB) mogli biti uzrocni cimbenici za nastanak AD. Zato predlažemo detaljnu analizu tih manje istraženih aspekata bolesti jer mogu doprinijeti objašnjenju agregacije tau proteina i neurofibrilarne patologije koja najbolje korelira s klinickim simptomima i napredovanjem bolesti. Naši su ciljevi: 1. ispitati odnose izmedu kognicije zdravih kontrola (HC), ispitanika s blagim spoznajnim oštecenjem (MCI) i ispitanika s AD s biološkim biljezima urodene imunosti u krvi i likvoru; osim niza neuropsiholoških testova, MR analize kortikalne atrofije i slušnih evociranih potencijala, stanje kognicije cemo procjenjivati testom skrivenog objekta pomocu vlastitog ALZENTIA® sustava; 2. odrediti propusnost BBB u HC, MCI, i AD ispitanika mjerenjem omjera albumina u likvoru i serumu te odredivanjem razine lakog lanca neurofilamenata i S100B proteina, kao i 24 metala, metaloida i elementa u tragovima; 3. procijeniti stupanj neuroimunološke aktivacije u sve 3 skupine ispitanika putem mjerenja vrijednosti TNF?, IL-1ß, VILIP-1, YKL-40, sTREM2, MCP1, CCL3, CCL4 i eotaksina-3 u krvi i likvoru te vizualizacijom neuroinflamacije i M1 mikroglije u postmortalnim uzorcima mozga (C1q, CD11b, CD68, CX3CR1, HLA-DR, Iba1, TREM2) i analize integriteta (prikaz akvaporinskih AQP4 kanala i kolagena tipa IV) i funkcije (prikaz LRP1, VDRLR i RAGE receptora) BBB u HC i AD, kao i mozgovima Wistar štakora inokuliranih patološkim tau oligomerima; i 4. Konstruirati luminescentni reporter za pracenje oligomerizacije tau proteina covjeka u živim stanicama kvasca, koje cemo koristiti za ispitivanje ucinka proteotoksicnog stresa i starenja na tau oligomerizaciju.

 

 

Project publications / Publikacije proistekle iz projekta

 

15. I. 2020 - 14. I. 2021

 

 

 

15. I. 2021 - 14. I. 2022

 

 

 

 

15. I. 2022. - 14. I. 2023

 

 


 

15. I. 2023 - 14. I. 2024

 

 


Presentations related to the project / Predavanja i prezentacije projekta

 

15. I. 2020 - 14. I. 2021

 

 

 

 

15. I. 2021 - 14. I. 2022

 

 

 

 

15. I. 2022 - 14. I. 2023

 

 

 

15. I. 2023 - 14. I. 2024

 

 

 


 

 

 

Please send questions related to the project to / Molimo šaljite pitanja vezana uz projekt na

goransimic@hotmail.com

 

 

page last updated on 24th Jun 2020 / stranica zadnji put obnovljena 24. lipnja 2020.

Hvala na posjeti - Thank you for coming!